Cantor reiterates Overweight rating on PolarityTE after meeting with doctors. After attending an event hosted by PolarityTE with Key Opinion Leaders and hearing three surgeons describe their clinical experiences using SkinTE, Cantor Fitzgerald analyst Elemer Piros said he believes PolarityTE is positioned long-term to “redefine the treatment landscape for wound regeneration.” He believes the fact that the shares are trading down 33% may be due to the market’s misunderstanding of the company’s IP strategy and interaction with the U.S. Patent and Trademark Office. Piros’ note to investors makes no mention of Citron Research, which earlier today accused PolarityTE of fraud related to its patent holdings and promotion of the patents to investors. Piros reiterates his Overweight rating and $65 price target on PolarityTE, which is down 32% to $26.42 in afternoon trading.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.